COMPARISON
Semaglutide vs Tirzepatide
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Semaglutide is authorised or registered in 10 and Tirzepatide in 10 of the 10 registers read. Semaglutide: highest phase Phase 4 (after approval). Tirzepatide: highest phase Phase 4 (after approval). 77 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Registered trials differs | 861 clinicaltrials.gov · 2026-10-03 | 309 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: OZEMPIC openfda · 2026-10-03T17:23:44.062Z | FDA-approved: MOUNJARO openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2018-02-08 ema · 2026-10-03 | 2022-09-15 ema · 2026-10-03 |
| ATC code differs | A10BJ06 ema · 2026-10-03 | A10BX16 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Semaglutide | placebo | Tirzepatide | placebo |
|---|---|---|---|---|
| Nausea | 19.5% | 4.5% | 25.6% | 8.1% |
| COVID-19 | 17.0% | 17.8% | 15.5% | 16.0% |
| Diarrhoea | 11.8% | 4.5% | 21.2% | 8.3% |
| Constipation | 8.9% | 2.8% | 13.7% | 4.5% |
| Vomiting | 8.6% | 1.6% | 11.4% | 2.6% |
| Decreased appetite | 6.3% | 1.3% | 11.6% | 2.9% |
| Dyspepsia | 5.3% | 1.2% | 7.9% | 2.7% |
| Headache | 4.0% | 2.1% | 6.6% | 6.2% |
| Upper respiratory tract infection | 2.7% | 1.9% | 5.7% | 6.2% |
| Nasopharyngitis | 7.5% | 6.1% | - | - |
| Abdominal pain | - | - | 6.0% | 2.7% |
Trial register Semaglutide: 50 placebo-controlled trials; Tirzepatide: 19. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Semaglutide side effects · Tirzepatide side effects
LEGAL STATUS
Approval in each country read
| Country | Semaglutide | Tirzepatide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
77 registered trials include both
| NCT06854614 | Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) ACTIVE_NOT_RECRUITING · updated 2026-09-30 |
|---|---|
| NCT07845500 | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity NOT_YET_RECRUITING · updated 2026-09-29 |
| NCT06779929 | Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes COMPLETED · updated 2026-09-18 |
| NCT07820111 | Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial COMPLETED · updated 2026-09-15 |
| NCT06897475 | A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide RECRUITING · updated 2026-09-14 |
| NCT06534411 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGL COMPLETED · updated 2026-09-09 |
| NCT06221969 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With COMPLETED · updated 2026-09-04 |
| NCT06803888 | Bariatric Surgery vs. Semaglutide vs. Tirzepatide ACTIVE_NOT_RECRUITING · updated 2026-09-03 |
| NCT07787936 | GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry NOT_YET_RECRUITING · updated 2026-08-26 |
| NCT07213323 | Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment RECRUITING · updated 2026-08-19 |
| NCT07202247 | Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients Du RECRUITING · updated 2026-08-17 |
| NCT07760532 | Comparing Facial Aging Between Identical Twins With 3D Imaging NOT_YET_RECRUITING · updated 2026-08-12 |
| 2023-509600-15-00 | Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. once weekly versus tirzepatide 5 mg s.c. once weekly in parti Not stated · updated 2026-08-03 |
| NCT06374875 | Fibrosis Lessens After Metabolic Surgery RECRUITING · updated 2026-07-31 |
| NCT07740291 | Tirzepatide Impact Assessment Study RECRUITING · updated 2026-07-31 |
| NCT07728812 | Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy NOT_YET_RECRUITING · updated 2026-07-27 |
| NCT07702461 | Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists RECRUITING · updated 2026-07-24 |
| NCT07720414 | Effects of GLP-1 RAs on Human Lactation Outcomes RECRUITING · updated 2026-07-22 |
| NCT07720466 | Salivary Function and Dental Changes During GLP-1 Therapy NOT_YET_RECRUITING · updated 2026-07-22 |
| NCT07057310 | Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women ENROLLING_BY_INVITATION · updated 2026-07-20 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.